AlzeCure Pharma (ALZCUR) Q1 2026 earnings summary

Executive summary

• Focused on advancing clinical programs for Alzheimer's and pain, with key progress in NeuroRestore ACD856 and Painless ACD440 projects.

• Received a €2.5 million grant from the European Innovation Council for Phase IIa trial in Alzheimer's with ACD856.

• Orphan drug designation for ACD440 granted by EMA in February 2026, adding to prior US designation.

• Presented new preclinical data at major international conferences, supporting both cognitive and pain indications.

Financial highlights

• Net sales for Q1 2026 were SEK 0 thousand, unchanged from the prior year.

• Operating loss increased to SEK -21,782 thousand from SEK -10,191 thousand year-over-year.

• Earnings per share, basic, was SEK -0.19 compared to SEK -0.11 in Q1 2025.

• Cash flow from operating activities was SEK -17,089 thousand, down from SEK -10,416 thousand.

• Cash and cash equivalents at period end were SEK 32,967 thousand, up from SEK 20,819 thousand.

Outlook and guidance

• Phase IIa clinical trial for NeuroRestore ACD856 in Alzheimer's expected to begin later in 2026.

• Preparations ongoing for registrational study in pain (ACD440) and for advancing Alzstatin ACD680 and TrkA-NAM ACD137 to clinical trials.

• Continued focus on business development and potential out-licensing agreements.